ATL1103/COR-004

In relation to Antisense Therapeutics Limited's ("ANP" or "the Company") ASX announcement yesterday regarding ANP's licensing partner Cortendo's Form 1 Registration Statement Prospectus (Prospectus), and for ease of reference, the Company provides Schedule 2 of Exhibit 10 of the Prospectus relating to the ATL1103/COR-004 executed Technology License Agreement.

ANP notes the following milestone events as:

- Start of the first Phase III Trial for ATL1103/COR-004 for the first Acromegaly Indication in any jurisdiction outside Australia & New Zealand;
- Filing of New Drug Application in the U.S. for ATL1103/COR-004 for the first Acromegaly Indication;
- Filing of Marketing Approval Application in the European Union for ATL1103/COR-004 for the first Acromegaly Indication;
- US Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first Acromegaly Indication;
- EU Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first Acromegaly Indication; and
- Japanese Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first Acromegaly Indication.

In addition, ANP is entitled to receive further payments based on achievement of the above milestones for a second indication in Acromegaly and/or with respect to any other endocrinology indication. There are also commercial milestones based on sales performance targets with respect to the first acromegaly indication. These payments in total would add up to US$124Million (A$177Million) if milestones are successfully achieved.

The Company would also like to confirm that the Milestone Shares Subscription as part of the potential milestone fees relating to the Start of the first Phase III Trial for an ATL1103 Product for the first Acromegaly Indication, which is referred to in Schedule 2, is a one off purchase of US$1M in ANP equity by Cortendo.

Furthermore, upon regulatory approval of ATL1103/COR-004 and achievement of sales performance targets, ANP would be entitled to royalty payments based on a percentage, ranging from the mid-single digits to the mid-teens, of net sales of ATL1103/COR-004.

Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed

from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

This agreement (together with all Schedules to this agreement) constitutes the entire agreement between the parties in connection with its subject matter and supersedes all previous agreements or understandings between the parties in connection with its subject matter, including the Non-Disclosure Agreement.

Schedule 1- Technology

[****]

Schedule 2 — Milestones

1. Clinical and Regulatory Milestones [1]

Milestone	Milestone Fee	
WITH RESPECT TO THE FIRST ACROMEGALY INDICATION		
	If In-Human Trial Milestone was a Phase III Trial	**If In-Human Trial Milestone was a Phase II B Trial**
Start of the first Phase III Trial for an ATL1103 Product for the first Acromegaly Indication in any jurisdiction in the Territory	US$[****], comprising: - $US[****] to be paid in accordance with clause 9.6; and - the Milestone Shares Subscription Price to be paid in accordance with clause 10.3	US$[****]
Filing of an NDA in the U.S. for an ATL1103 Product for the first Acromegaly Indication	US$[****]	US$[****]
Filing of an MAA in the EU: (a) through the centralized procedure; or (b) in at least 3 of the 5 major markets in the EU comprised of the United Kingdom, France, Germany, Italy or Spain); or (c) the date that is six calendar months after filing in at least 1 of the one of the following countries; the United Kingdom, France, Germany, Italy or Spain, whichever occurs first, for an ATL1103 Product for the first Acromegaly Indication	US$[****]	US$[****]
US Approval (excluding Pricing Approval) for an ATL1103 Product for the first Acromegaly Indication	US$[****]	US$[****]
EU Approval (excluding Pricing Approval) for an ATL1103 Product for the first Acromegaly Indication	US$[****]	US$[****]
Japanese Approval (excluding Pricing Approval) for an ATL1103 Product for the first Acromegaly Indication	US$[****]	US$[****]

[1] For the avoidance of doubt, if the In-Human Trial Milestone is a Phase III Trial, then the Milestone Fees in the second column of the above table apply and the third column of the above table no longer has any application or relevance under this agreement.

Milestone	Milestone Fee

WITH RESPECT TO THE SECOND ACROMEGALY INDICATION

	If In-Human Trial Milestone was a Phase III Trial	If In-Human Trial Milestone was a Further Phase II B Trial
Start of a Phase III Trial for an ATL1103 Product for the second Acromegaly Indication in any jurisdiction in the Territory	US$[****]	US$[****]
Filing of an NDA in the U.S. for an ATL1103 Product for the second Acromegaly Indication	US$[****]	US$[****]
Filing of an MAA in the EU: (a) through the centralized procedure; or (b) in at least 3 of the 5 major markets in the EU comprised of the United Kingdom, France, Germany, Italy or Spain); or (c) the date that is six calendar months after filing in at least 1 of the one of the following countries; the United Kingdom, France, Germany, Italy or Spain, whichever occurs first, for an ATL1103 Product for the second Acromegaly Indication	US$[****]	US$[****]
U.S. Approval (excluding Pricing Approval) for an ATL1103 Product for the second Acromegaly Indication	US$[****]	US$[****]
EU Approval (excluding Pricing Approval) for an ATL1103 Product for the second Acromegaly Indication	US$[****]	US$[****]

Milestone	Milestone Fee
WITH RESPECT TO ANY OTHER INDICATION	
Start of a Phase III Trial for an ATL1103 Product for any Other Indication in any jurisdiction in the Territory	US$[****]
Filing of an NDA in the U.S. for an ATL1103 Product for any Other Indication	US$[****]
Filing of an MAA in the EU for an ATL1103 Product for any Other Indication	US$[****]
U.S. Approval (excluding Pricing Approval) for an ATL1103 Product for any Other Indication	US$[****]
EU Approval (excluding Pricing Approval) for an ATL1103 Product for any Other Indication	US$[****]
Japanese Approval (excluding Pricing Approval) for an ATL1103 Product for any Other Indication	US$[****]

2. Commercial Milestones [2]

Milestone	Milestone Fee
WITH RESPECT TO THE FIRST ACROMEGALY INDICATION	

	If In-Human Trial Milestone was a Phase III Trial	If In-Human Trial Milestone was a Further Phase II B Trial
Aggregate Net Sales in a Calendar Year of US$[****]	US$[****] (once off)	US$[****] (once off)
Aggregate Net Sales in a Calendar Year of US$[****]	US$[****] (once off)	US$[****] (once off)
Aggregate Net Sales in a Calendar Year of US$[****]	US$[****] (once off)	US$[****] (once off)
Aggregate Net Sales in a Calendar Year of US$[****]	US$[****] (once off)	US$[****] (once off)
Aggregate Net Sales in a Calendar Year of US$[****]	US$[****] (once off)	US$[****] (once off)

[2] For the avoidance of doubt, (i) if the In-Human Trial Milestone is a Phase III Trial, then the Milestone Fees in the second column of the above table apply and the third column of the above table no longer has any application or relevance under this agreement; and (ii) each of the Commercial Milestone Fees shall be paid only one time, upon the first achievement of such event in any Calendar Year.

Schedule 3 — ATL1103 higher dose study

A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly

Budget	$ (AUD)
Clinical Monitoring, Data Management & CSR	[****]
Site costs / StV & PARC	[****]
Shipping	[****]
Central Lab assays	[****]
IMP, Storage, shipping & labelling	[****]
Medical Monitoring & DSMB	[****]
Additional Stability/ref standard	[****]
PK & Complement	[****]
MRI & central reader	[****]
Out of scope	[****]
Travel	[****]
TOTAL	**$ [****]**

TRIAL OUTLINE

Study Title:	A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.
Protocol Number:	1103-CT03
Test Drug:	ATL1103
Route of Administration:	Subcutaneous
Indication:	Acromegaly
Study Sponsor:	Antisense Therapeutics Limited 6 Wallace Avenue Toorak Victoria 3142 Australia Telephone +61 3 9827 8999
Protocol Version:	2.0
Date:	11 December 2014

CONFIDENTIALITY STATEMENT

All information relating to the study drug, Investigator's Brochure, Clinical Protocol, Case Report Forms and any information and results developed during, or arising from the study, is considered confidential and proprietary information of Antisense